Leqembi’s Global Sales Reach $67 Million, Yet US Adoption Faces Hurdles
Global Sales:
Leqembi, an Alzheimer's disease treatment developed by Biogen in partnership with Eisai, achieved global sales of $67 million in the third quarter of 2024.
US Adoption Challenges:
Despite the significant global sales, the adoption of Leqembi in the US remains a challenge, indicating potential market and regulatory hurdles.
Partnership:
Leqembi is a product of the partnership between Biogen and Eisai, highlighting the collaborative efforts in the pharmaceutical industry to address complex diseases like Alzheimer's.
Market Performance:
The sales figures indicate a mixed performance for Leqembi, with strong global sales but slower adoption in the US market, which is a critical region for pharmaceutical sales.